# A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

> **NCT04147819** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 14 (actual)

## Conditions studied

- Cancers With HER2 Expression

## Interventions

- **DRUG:** BAY2701439
- **DRUG:** BAY2701439

## Key facts

- **NCT ID:** NCT04147819
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-02
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-09-26
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147819, "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04147819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*